Home › Companies › CLYM

Climb Bio, Inc.

CLYM Rare disease Lead: Phase 2 3 Biotech Distilled articles ↓

Hematology Immunology Renal Protein Small Molecule

Most recent annual filing: 2026-03-05

Pipeline (7 active programs)

budoprutug

Protein Target: CD19

Primary Membranous Nephropathy Phase 2 intravenous
Immune Thrombocytopenia Phase 2 intravenous
Systemic Lupus Erythematosus Phase 1 intravenous
Systemic Lupus Erythematosus Phase 1 subcutaneous
Primary Membranous Nephropathy Phase 1 subcutaneous

CLYM116

Protein Target: APRIL

IgA Nephropathy Phase 1 Mabworks

ETX-123

Small Molecule Target: Kv7.2/3

Undisclosed indication

Biotech Distilled coverage (3)

2026-05-06 UPDATE: Climb Bio (CLYM) - The SC Wedge Lands 🔒 Paid
2026-04-29 UPDATE: Climb Bio (CLYM) - The Smart Money Doubles Down 🔒 Paid
2026-04-23 Climb Bio (CLYM) - Scientific Deep Dive for Budoprutug and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.